TFF Pharmaceuticals, Inc. (TFFP), the developer of drug products based on Thin Film Freezing technology platform, announced Tuesday positive initial data from its ongoing Phase 2 trials of TFF VORI and TFF TAC, along with clinical data from the ongoing TFF VORI Expanded Access Program or EAP.
New multi-centric, phase-II, randomized, open-label clinical trial evaluates efficacy, safety and tolerability of NIclosamide for the treatment of hospitalized COVID-19 patients.